Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis

Inclusion Criteria:

• Diagnosis of gMG [Myasthenia Gravis Foundation of America (MGFA) Class II-IV] atScreening

• Positive serology for acetylcholine receptor (AChR) autoantibodies

• MG-ADL Score of ≥ 6 at Screening and Baseline

• QMG score ≥ 12 at Screening and Baseline

• No change in corticosteroid dose for at least 30 days prior to Baseline oranticipated to occur during the 12-week Treatment Period

• No change in immunosuppressive therapy, including dose, for at least 30 days priorto Baseline or anticipated to occur during the 12-week Treatment Period

Exclusion Criteria:

• Thymectomy within 12 months prior to Baseline or scheduled to occur during the 12week Treatment Period

• History of meningococcal disease

• Current or recent systemic infection within 2 weeks prior to Baseline or injectionrequiring intravenous (IV) antibiotics within 4 weeks prior to Baseline